Baxter International INC

Baxter International Inc. has commenced cash tender offers to purchase up to $500 million of its outstanding senior notes, aiming to optimize its debt structure.

Baxter International Inc. announced second-quarter 2026 results, exceeding expectations with sales growth and raising its full-year financial outlook.

Baxter International Inc. is updating its reporting segments to align with its new operating model, effective from the second quarter of 2026, with no impact on previously reported consolidated financial statements.

Baxter International Inc. announced first-quarter 2026 results, with sales from continuing operations reaching $2.7 billion, and reiterated its full-year financial outlook.

Baxter International Inc. provided an update on its leadership transitions, strategic initiatives, 2025 financial performance, and corporate governance in a recent stockholder engagement presentation.

Baxter International Inc. announced the departure of CFO Joel Grade, effective March 16, 2026, and the immediate appointment of Anita Zielinski as interim CFO.

Baxter International reports Q2 2026 results with increased net sales and operating income, despite ongoing business transformation and supply chain challenges.

Baxter International Inc. reported a net loss of $15 million for the first quarter of 2026 as it navigates restructuring costs and regulatory challenges following the divestiture of its Kidney Care business.

Baxter International Inc. reported a net loss for the third quarter of 2025, impacted by significant special items including tax reserves and costs related to the Novum LVP recall, despite overall sales growth.

Baxter International reports mixed Q2 2025 results with increased sales and significant debt reduction, offset by margin compression and operational challenges.

Baxter International's Q1 2025 results show increased net income driven by the sale of its Kidney Care business, despite ongoing supply chain challenges and macroeconomic uncertainties.

Baxter International's Q3 results show a net income of $140 million, impacted by special items and the pending sale of its Kidney Care business, alongside challenges from Hurricane Helene.

Baxter International Inc. posted a net loss of $957 million in 2025, driven by significant impairment charges and product recalls, despite operational sales growth.

Baxter International Inc.'s 2024 10-K filing reveals a year of strategic shifts, including the sale of the Kidney Care business and a new operating model, alongside financial results impacted by Hurricane Helene and global economic conditions.

Baxter International Inc.'s 2023 10-K filing details a year of strategic changes, including a planned Kidney Care business spinoff, a new operating model, and the sale of its BioPharma Solutions business, alongside a review of its financial performance.

Anita A. Zielinski, SVP, Interim CFO, CAO & Cntrlr at Baxter International Inc., received a special grant of restricted stock units.

Steven P. Wallace, President of Advanced Surgery at Baxter International Inc., reported a transaction involving the forfeiture of shares to cover tax withholding.

Baxter International Inc. director David S. Wilkes received a grant of 12,836 fully vested shares of common stock.

Baxter International Inc. director Amy McBride Wendell received a grant of 12,836 fully vested shares of common stock on May 5, 2026.

Baxter International Inc. Director Patricia Morrison acquired 12,836 shares of common stock on May 5, 2026, as part of a grant.

Baxter International Inc. director Jeffrey A. Craig received a grant of 12,836 fully vested shares of common stock.

Baxter International Inc. reports a challenging 2025 with significant leadership changes and strategic divestitures, as it embarks on a turnaround strategy.

Baxter International Inc. announces its 2025 Annual Meeting and provides details on voting procedures and proposals.

Baxter International completed the sale of its Kidney Care business and announced leadership changes as part of a strategic transformation.

Baxter International Inc. has issued a supplement to its proxy statement clarifying the impact of broker non-votes on certain proposals at the upcoming 2024 Annual Meeting of Stockholders.

Baxter International Inc. announces its 2024 Annual Meeting and provides details on proposals for stockholder voting, including the election of directors, executive compensation, and amendments to the incentive plan and corporate charter.

Baxter International is targeting the second half of 2024 for the separation of its Kidney Care business, alongside other strategic initiatives to enhance operational effectiveness and shareholder value.

FMR LLC and Abigail P. Johnson have filed a Schedule 13G reporting a 10.3% beneficial ownership stake in Baxter International Inc.

FMR LLC and Abigail P. Johnson have reported a combined beneficial ownership of 9.0% in Baxter International Inc. as of March 31, 2026.

Vanguard Capital Management has reported beneficial ownership of 38,033,907 shares, representing 7.36% of Baxter International Inc.'s common stock as of March 31, 2026.

Pzena Investment Management LLC has reported a significant beneficial ownership stake of 12.7% in Baxter International Inc. as of March 31, 2026.

The Vanguard Group reports 0% beneficial ownership in Baxter International Inc. following an internal realignment.

BlackRock Portfolio Management LLC has reported an 8.7% beneficial ownership stake in Baxter International Inc., totaling 44,925,341 common shares.